Pluristem Therapeutics Inc. (PSTI.OB), a leading bio-therapeutics company, announced that NASDAQ has approved the company’s application to list their common stock on the NASDAQ Capital Market. The Company’s common stock will begin trading on this market December 10, 2007 under the symbol PSTI.
Zami Aberman, Pluristem’s President and CEO, commented, “Pluristem is proud to begin trading on the NASDAQ Capital Market system. We believe that NASDAQ is the right platform to support our business growth aspirations. I am confident that our listing will facilitate broader interest in our common stock from both institutional and individual investors.”
The NASDAQ listing approval is still contingent upon the full compliance with all applicable listing standards. Such standards include trading at a stock price of $4.00 or greater, as well as disclosing all corporate financials. If such standards are not met, Pluristem’s listing may be rescinded at any time.
Pluristem Therapeutics, Inc. is a leading bio-therapeutics company focused on the commercialization of non-personalized stem cells. The company intends to use such cells to treat numerous severe degenerative, malignant and autoimmune disorders.
Let us hear your thoughts below: